Eastman Chemical's statutory earnings may have been distorted by unusual items, suggesting that its true underlying earnings power could be less than its statutory profit. There are also 2 warning signs for Eastman Chemical that investors should be aware of.
EPS growth and falling share price mismatch suggests a shift in market perception of the company. Recent sell-off could be a long-term growth opportunity, but investors should heed 2 warning signs for Eastman Chemical.
A decline in earnings per share and ongoing risk to future dividends make Eastman Chemical less appealing for dividend-focused investors despite efforts to increase the dividend payout ratio.
Despite Eastman Chemical's fair trading price, future buying opportunities may arise from the stock's volatility. The company's bright outlook, propelled by a predicted profit doubling, might lead to increased cash flow and share valuation. However, a thorough balance sheet analysis is recommended before investing.
Analyst Jeffrey Zekauskas from J.P. Morgan predicts Eastman Chemical's earnings to rebound in 2024. Poor performance in 2023 due to market challenges, but possible recovery driven by dividends and good free cash flow expected.
GOLDMAN SACHS •$ボシュロム(BLCO.US)$Goldman Sachs analyst Amit Hazan initiated coverage of Bausch + Lomb with a Neutral rating and $22 price target, implying 22% upside potential. The analyst sees Bausch + Lomb's current offering and pipeline as positioning it well to maintain or expand share in the "attractive and durable' eye care market. •$スチール・ダイナミクス(STLD.US)$Goldman Sachs analyst Emily Chieng downgraded Steel Dynamics to Neutral...
Gainers: •$Checkmate Pharmaceuticals(CMPI.US)$+331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash) •$アクサム・セラピューティクス(AXSM.US)$+27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder) •$スーパー・マイクロ・コンピューター(SMCI.US)$+14.3% (earnings report) •$プラグパワー(PLUG.US)$+9.24% (t...
Upgrades •$テクニップFMC(FTI.US)$: Societe Generale Upgrades to uy from Hold - PT $10 •$ルルレモン・アスレティカ(LULU.US)$: Truist Securities Upgrades to Buy from Hold - PT $495 (from $390) •$ノースウェスタン(NWE.US)$: Barclays Upgrades to Equal Weight From Underweight - PT $62 (from $57) •$ポートランド・ジェネラル・エレクトリック(POR.US)$: Barclays Upgrades to EqualWeight From Underweight - PT $57 (from $53) •$プライススマート(PSMT.US)$: Scotiabank Upgrades to Sector Outperform Fro...
イーストマン・ケミカルに関するコメント
コラムToday's Pre-Market Stock Movers: ORCL, RENT, U, AKRO and More
In reaction to earnings/guidance:
• $プラネット・ラボスPBC(PL.US)$ +11.3%,$コア・メイン(CNM.US)$ +6.1%,$リーガル・レクスノード(RRX.US)$ +2% (reaffirms outlook),$オラクル(ORCL.US)$ +1.6%
Other news:
• $アケロ・セラピューティクス(AKRO.US)$ +93.2% (reports Phase 2b HARMONY Study)
• $Akouos(AKUS.US)$ +10.3% (FDA clears IND application to initiate a Phase 1/2 first in human pediatric clinical trial of AK-OTOF)
• $カタリスト・ファーマシューティカルズ(CPRX.US)$ +7.7...
コラムAnalysts' screen on BLCO, SNAP, TSLA, ZM and more
•$ボシュロム(BLCO.US)$ Goldman Sachs analyst Amit Hazan initiated coverage of Bausch + Lomb with a Neutral rating and $22 price target, implying 22% upside potential. The analyst sees Bausch + Lomb's current offering and pipeline as positioning it well to maintain or expand share in the "attractive and durable' eye care market.
•$スチール・ダイナミクス(STLD.US)$ Goldman Sachs analyst Emily Chieng downgraded Steel Dynamics to Neutral...
コラムTop upgrades and downgrades on 5/31
• $グラブ・ホールディングス(GRAB.US)$: Bernstein Upgrades to Outperform from Market Perform - PT $3.04
• $リンデ(LIN.US)$: Evercore ISI Upgrades to Outperform from In Line - PT $355
• $Magellan Midstream(MMP.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT $56 (from $54)
• $マーキュリー・システムズ(MRCY.US)$: Baird Upgrades to Outperform from Neutral - PT $72 (from $56)
• $ニューリックス・セラピューティクス(NRIX.US)$: Wells Fargo Upgrades to Overweight from EqualWeight - PT...
コラムToday's pre-market stock movers: PLUG, CMPI, JNJ, LMT and more
• $Checkmate Pharmaceuticals(CMPI.US)$ +331.5% (Regeneron Pharma (REGN) to acquire CMPI for $10.50/share in cash)
• $アクサム・セラピューティクス(AXSM.US)$ +27.9% (received and agreed to Postmarketing Requirements/Commitments proposed by the FDA with respect to the New Drug Application for its AXS-05 product candidate for the treatment of major depressive disorder)
• $スーパー・マイクロ・コンピューター(SMCI.US)$ +14.3% (earnings report)
• $プラグパワー(PLUG.US)$ +9.24% (t...
コラムTop upgrades and downgrades on 4/19
• $テクニップFMC(FTI.US)$ : Societe Generale Upgrades to uy from Hold - PT $10
• $ルルレモン・アスレティカ(LULU.US)$ : Truist Securities Upgrades to Buy from Hold - PT $495 (from $390)
• $ノースウェスタン(NWE.US)$ : Barclays Upgrades to Equal Weight From Underweight - PT $62 (from $57)
• $ポートランド・ジェネラル・エレクトリック(POR.US)$ : Barclays Upgrades to EqualWeight From Underweight - PT $57 (from $53)
• $プライススマート(PSMT.US)$ : Scotiabank Upgrades to Sector Outperform Fro...
まだコメントはありません